α-Synuclein-IN-24
α-Synuclein-IN-24 is an α-synuclein (α-Syn) aggregation inhibitor with an IC50 of 4.0 μM. α-Synuclein-IN-24 stabilizes the secondary conformation of α-synuclein monomers, inhibits β-sheet formation, reduces oligonucleation during the aggregation lag phase, dissociates preformed aggregates, and blocks reaggregation. α-Synuclein-IN-24 reduces α-synuclein inclusions in neuronal cells and scavenges ROS. α-Synuclein-IN-24 can be used for the research of Parkinson's disease.
For research use only. We do not sell to patients.
- CAS No.: 2883627-56-1
- Formula: C22H17FN2O4
- Molecular Weight:392.38
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All α-synuclein Isoforms
More
Biological Activity
Description
In Vitro
α-Synuclein-IN-24 (Compound 2dc) (30 μM; 96 h) inhibits the aggregation of purified human α-synuclein at all stages of the entire aggregation process, reduces the aggregation rate constant to 0.107 h−1, and when incubated at a concentration of 30 μM for 96 h, its main mechanism of action is to reduce the formation of oligomeric nuclei during the lag phase[1].
α-Synuclein-IN-24 (30 μM; 88 h) reduces the formation of large, interconnected purified human α-synuclein fibrils, and incubation at 30 μM for 88 h produces shorter, sparser fibrils[1].
α-Synuclein-IN-24 (30 μM; 0-88 h) effectively depolymerizes preformed purified human α-synuclein aggregates and inhibits their re-aggregation; when added at a concentration of 30 μM during the lag phase (21 h), it achieves the highest re-aggregation inhibition rate of up to 76.6%[1].
α-Synuclein-IN-24 (10 μM; 48 h) inhibits the formation of α-synuclein (α-Syn) inclusions in plasmid-transfected human glioma H4 cells[1].
α-Synuclein-IN-24 (3-10 μM; 30 min) dose-dependently scavenges reactive oxygen species (ROS) in human glioma H4 cells, and reduces ROS production to approximately 30% of that in the H2O2-treated control group at a concentration of 10 μM[1].
α-Synuclein-IN-24 (1-100 μM; 24 h) exhibits cytotoxicity in human glioma H4 cells: the cell survival rate is < 85% at the concentration of 100 μM, whereas it shows a slight pro-proliferative effect after 24 h incubation at concentrations of 1-3 μM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:human neuroglioma H4 cells, human neuroblastoma SH-SY5Y cells
-
Concentration:1, 3, 10, 30, 100 μM
-
Incubation Time:24 h
-
Result:Reduced H4 cell viability to below 85% at concentrations up to 100 μM.
Showed slight proliferation effects at lower concentrations (1-3 μM).
Chemical Information
-
CAS No. 2883627-56-1
-
Molecular Weight 392.38
-
Formula C22H17FN2O4
-
SMILES
OC(C=C1/C=C/C(NC(C=C2)=CC=C2NC(C3=CC=C(C=C3)F)=O)=O)=C(C=C1)O
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
ROS/oxidative-stress fluorescent staining
ROS/oxidative-stress fluorescent staining uses cell-permeant fluorogenic probes that become fluorescent after oxidation inside cells or tissues; commonly used examples include DCFH-DA/DCFDA for broad cellular oxidant detection, DHE for superoxide-related signal detection, MitoSOX for mitochondrial superoxide-related signal detection, and CellROX probes for oxidative-stress-associated fluorescence readouts. The assay detects probe oxidation rather than a single ROS species unless the probe and analysis method have been chemically validated for that species. DCFH-DA enters cells, is deacetylated by intracellular esterases to DCFH, and produces fluorescent DCF after oxidation, so the readout is used as an operational measure of total cellular oxidative stress rather than a species-specific ROS measurement. DHE and MitoSOX can report superoxide-related oxidation, but red fluorescence alone can include non-specific ethidium-like oxidation products; HPLC or optimized spectral approaches are
-
Human pluripotent stem cell midbrain dopaminergic neuron differentiation
Human pluripotent stem cells are directed toward midbrain dopaminergic neurons by first inducing a neural floor-plate-like progenitor state, then patterning cells with ventralizing SHH signaling and midbrain/WNT-FGF cues, and finally maturing progenitors into neurons expressing dopaminergic markers such as TH, NURR1/NR4A2, PITX3, DAT/SLC6A3, VMAT2/SLC18A2, GIRK2/KCNJ6, FOXA2, LMX1A, and EN1. The main readouts are loss of pluripotency, acquisition of FOXA2+/LMX1A+ midbrain floor-plate progenitors, emergence of βIII-tubulin+/MAP2+ neurons, and production of TH+ dopaminergic neurons with molecular, dopamine-release, and electrophysiological features of midbrain dopaminergic identity.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)